EP1442063A2 - Anticorps a anti-n-glycolyl-acide neuraminique et leur utilisation pour determiner la presence de glycoproteines - Google Patents

Anticorps a anti-n-glycolyl-acide neuraminique et leur utilisation pour determiner la presence de glycoproteines

Info

Publication number
EP1442063A2
EP1442063A2 EP02785382A EP02785382A EP1442063A2 EP 1442063 A2 EP1442063 A2 EP 1442063A2 EP 02785382 A EP02785382 A EP 02785382A EP 02785382 A EP02785382 A EP 02785382A EP 1442063 A2 EP1442063 A2 EP 1442063A2
Authority
EP
European Patent Office
Prior art keywords
antibodies
glycoproteins
dsm
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02785382A
Other languages
German (de)
English (en)
Inventor
Rudolf Grimm
Carsten Brockmeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal Biotech Forshungs GmbH
Original Assignee
Hexal Biotech Forshungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Biotech Forshungs GmbH filed Critical Hexal Biotech Forshungs GmbH
Publication of EP1442063A2 publication Critical patent/EP1442063A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Definitions

  • the present invention relates to antibodies for the determination of
  • Glycoproteins and hybridoma cells that produce these antibodies are Glycoproteins and hybridoma cells that produce these antibodies.
  • the invention further relates to specific antigens that induce the formation of these antibodies.
  • the invention relates to the use of these antibodies in immunoassays for the determination of glycoproteins.
  • Naturally occurring biological substances such as proteins play an important role in numerous fields of application, for example in medicine and in food technology.
  • Such substances are either isolated from animal or vegetable sources or, not least because of the associated economic advantages, by methods of genetic engineering, in particular by overexpression of recombinant DNA in a suitable host cell.
  • glycoproteins are an important group of proteins in eukaryotic cells.
  • the glycoproteins include, for example, many serum and plasma proteins, the blood group substances, antibodies, lectins, and many enzymes, receptors and proteohormones, some of which are already used in human and veterinary medicine.
  • Important known glycoproteins that are already used in medicine include: Erythropoietin (EPO), intrinsic factor and interferons.
  • EPO Erythropoietin
  • Glycoproteins are proteins with a number covalently attached to the
  • Bound oligosaccharide polypeptide chain These are generally shorter branched heteropolysaccharides which are linked to the peptide portion by O- or N-glycosidic bonds.
  • the attachment of the sugar residues to the polypeptide chains with the formation of the glycoproteins is a co- and post-translational modification of the polypeptides, which is carried out in eukaryotic cells by specific glycosyltransferases and predominantly in the endoplasmic Reticulum and in the Golgi apparatus.
  • the heteropolysaccharides bound to the polypeptide chain almost always contain
  • N-acetylhexosamine and hexoses usually galactose, mannose and / or glucose
  • N-acetylneuraminic acid usually galactose, mannose and / or glucose
  • N-acetylneuraminic acid usually galactose, mannose and / or glucose
  • N-acetylneuraminic acid usually galactose, mannose and / or glucose
  • Devine et al. also a monoclonal antibody that specifically binds to mucins expressed in tumor cells with O-linked carbohydrate residues containing an N-glycolylneuraminic acid residue.
  • glycosylation is often important for the biological function of the glycoproteins
  • recombinantly produced human proteins should be largely identical to the corresponding naturally occurring endogenous proteins.
  • host cells that are able to generate glycosylation patterns that are as similar as possible to human proteins are generally used in the production by genetic engineering.
  • the advantageous and desirable genetic engineering production of glycoproteins which are not only functionally identical but structurally almost identical to the corresponding naturally occurring proteins, often also leads to the problem that the artificially produced product is no longer analytically or only very difficult can be distinguished from the protein in its natural form.
  • the object of the present invention is therefore to rapidly and specifically detect glycoproteins expressed in non-human eukaryotic cells or in degenerate human cells, for example recombinant human glycoproteins.
  • the invention therefore relates to monoclonal antibodies which bind specifically to glycoproteins, the N-glycan chains with a include terminal glycosidically bound N-glycolylneuraminic acid, and which do not bind glycoproteins with N-glycan chains that do not carry terminally glycosidically bound N-glycolylneuraminic acid, and derivatives of these antibodies.
  • N-glycan chains are to be understood as the naturally occurring oligosaccharides which are linked via N-glycosidic to the polypeptide chain via asparagine residues and which have an N-acetylneuraminic acid in the form of a Neu5Ac- ⁇ - (2-> 3) at their free end.
  • N-Galactose-ß- (1- »4) N-acetylglucosamine residues.
  • N-Glycan chains with a terminally glycosidically bound N-glycolylneuraminic acid “are to be understood as the corresponding oligosaccharides, in which the terminal N-acetylneuraminic acid by N-glycolylneuraminic acid is substituted.
  • Derivatives of the antibodies according to the invention are understood to mean fragments of these antibodies and modified antibodies or antibody fragments in which the binding specificity of the antibodies or fragments is retained. Fragments of the antibodies according to the invention are, in particular, those which comprise the antigen binding region of the antibodies, for example Fab, Fab 'or F (ab') 2 fragments.
  • Modified antibodies or fragments are - for example chemically or enzymatically - modified antibodies or fragments, for example radioactive, for example with iodine ( 125 l or 131 l), carbon ( 14 C) or sulfur ( 35 S), or with a fluorochrome, for example fluorescein isothiocyanate (FITC), tetramethylrhodamine isothiocyanate (TRITC) phycoerythrin (PE) or dichlorotriazine fluorescein (DTAF), labeled antibodies or antibody fragments, and conjugates of the antibodies or fragments with enzymes such as horseradish peroxidase, alkaline phosphatase, ß-D-galucose oxidase, Glucoamylase, carbonic anhydrase or acetylcholinesterase.
  • enzymes such as horseradish peroxidase, alkaline phosphatase, ß-D-galucose oxidase
  • Glycoproteins which comprise N-glycan chains with a terminally glycosidically bound N-glycolylneuraminic acid are almost all glycoproteins with N-glycan chains which are expressed in non-human eukaryotic cells and in degenerate human cells, since the terminally occurring almost exclusively in healthy human cells N-acetylneuraminic acid of the N-glycan chain in non-human eukaryotic cells and in degenerate human cells is partially substituted by N-glycolylneuraminic acid.
  • the N-glycan chains of recombinant human glycoproteins expressed in non-human eukaryotic cells also contain terminal N-glycolylneuraminic acid residues, while the corresponding homologous endogenous glycoproteins from healthy human cells contain only N-acetylneuraminic acid residues wear.
  • the antibodies according to the invention are now able, regardless of the protein structure, to bind to N-glycan chains with a terminally glycosidically bound N-glycolylneuraminic acid, so that, for example, recombinant human glycoproteins can be distinguished from the corresponding endogenous human proteins using the antibodies according to the invention.
  • the antibodies according to the invention can bind to the sugar structures with a terminal N-glycolylneuraminic acid regardless of the structure of the total protein, these antibodies can be used to specifically detect glycoproteins that have been expressed in non-human or degenerate human cells.
  • the antibodies according to the invention react specifically with recombinant glycoproteins produced in non-human cells, for example CHO cells, BHK cells or insect cells, for example recombinant human glycoproteins such as erythropoietin, tissue plasminogen activator and colony-stimulating factors (CSF ), Follicle-stimulating hormone, intrinsic factor, factor VII, factor VIII or interferons and interleukins, for example ⁇ -interferon (IFN- ⁇ ), while they do not bind to the corresponding endogenous glycoproteins from healthy human cells.
  • non-human cells for example CHO cells, BHK cells or insect cells
  • human glycoproteins such as erythropoietin, tissue plasminogen activator and colony-stimulating factors (CSF ), Follicle-stimulating hormone, intrinsic factor, factor VII, factor VIII or interferons and interleukins, for example ⁇ -interferon (IFN- ⁇ )
  • IFN- ⁇ ⁇ -interferon
  • the antibodies according to the invention bind with high specificity to oligosaccharide structures which have terminal N-glycolylneuraminic acid residues which are linked via an ⁇ - (2-3) glycosidic bond to the neighboring monosaccharide unit, a galactosyl residue.
  • the antibodies according to the invention bind to oligosaccharides with three or more monosaccharide units which carry a Neu5Gc- ⁇ - (2-> 3) ⁇ galactose- ß- (1 -> 4) -N-acetylglucosamine residue.
  • the antibodies according to the invention can belong to any class of immunoglobuins, but are preferably IgG or IgM antibodies, particularly preferably IgG antibodies, for example the IgG ⁇ subclass.
  • the present invention therefore also relates to synthetic oligosaccharide antigens which comprise an oligosaccharide which is optionally coupled to a support via a spacer and which contains a terminally glycosidically bound N-glycolylneuraminic acid.
  • Preferred oligosaccharide antigens are those in which the terminal N-glycolylneuraminic acid is linked via an ⁇ -glycosidic bond to the adjacent monosaccharide unit, for example a D-galactosyl residue.
  • the N-glycolylneuraminic acid is preferably linked to a D-galactosyl radical via an ⁇ - (2 ⁇ 3) -, an ⁇ - (2 ⁇ 4) - or an ⁇ - (2-> 6) -glycosidic bond.
  • the oligosaccharide coupled to the support has at least three monosaccharide units, and particularly preferred oligosaccharide antigens include as the trisaccharide group a Neu5Gc- ⁇ - (2-3) -galactose- ⁇ - (1-4) -N-acetylglucosamine group of the Formula I.
  • Suitable carrier molecules are, for example, numerous natural or synthetic high-molecular proteins. Proteins that are usually used for the production of antigens are, for example, serum albumin, such as bovine serum albumin (BSA), human serum albumin, or rabbit serum albumin, serum globulin, thyroglobulin, hemocyanine, such as keyhole limpet hemocyanin (KLH), polylysine, polyglutaminic acid or lycine copolymers. Preferred carrier molecules are BSA and KLH. Carrier molecules which are themselves not or only weakly immunogenic are advantageously used, so that the immune response is directed preferably or exclusively against the trisaccharide structure. A preferred carrier molecule in this sense is, for example, BSA.
  • the oligosaccharide structure can also be coupled to the carrier via a spacer.
  • a “spacer” is to be understood here as bridge members which are inserted between the oligosaccharide and the carrier.
  • the spacers are expediently bridge members with 1 to 20, in particular with 2 to 10, atoms.
  • the spacer groups can be selected from a large number of groups known to the person skilled in the art.
  • Suitable spacers are, for example, alkylene groups with 1 to 20 carbon atoms, preferably with 2 to 15, for example 2 to 10 carbon atoms. Alkylene groups with 3 carbon atoms have proven to be very suitable.
  • the oligosaccharide (hapten) can be coupled to the carrier in various ways.
  • the hapten can be bound to a carrier molecule like a protein by isothiocyanate coupling, coupling with diazo compounds, coupling via amide bonds, coupling by means of reductive amination, coupling by means of glutaraldehyde or coupling by means of guanidine (see also Advances in Carbohydrate Chemistry and Biochemistry, Vol. 37, pp.
  • the present invention also relates to trisaccharides of the general formula II
  • Z represents a hydrogen atom or a group B-X, where X represents a reactive group via which the trisaccharide can be coupled to a support, and B represents a single bond or the above-mentioned spacer group.
  • the reactive group X via which the trisaccharide can be coupled to the carrier, can be selected from a large number of reactive groups, for example -NH 2 , -CHO, -NCS, -I, -S0 2 -Hal, in which Hai F, Cl , Br or I means, or -COOH.
  • a particularly suitable trisaccharide or hapten molecule which can be coupled to a carrier is, for example, the trisaccharide Neu5Gc- ⁇ - (2- »3 ') - lactosamine-3-aminopropylglycoside of the formula III provided with a spacer
  • the carriers are the above-mentioned carrier molecules known to those skilled in the art, and the haptens can be coupled as described above.
  • oligosaccharides according to the invention can be prepared, for example, in accordance with the process described in the following example using the preparation of the trisaccharide of the formula III according to the invention (cf. Sherman et al. (Carbohydr. Res. 330: 445-458, 2001).
  • the trisaccharides thus obtained can then be coupled to a carrier, for example BSA or KLH, in a manner known per se, preferably by means of reductive amination or by means of glutaraldehyde.
  • a carrier for example BSA or KLH
  • oligosaccharide antigens according to the invention can be prepared in a manner known per se
  • Antibodies are used. For this purpose, mammals who have become
  • mice in particular Balb / c mice and NMRI mice,
  • antigens are those which comprise a trisaccharide of the formula I which is coupled to KLH or BSA as a carrier.
  • the antigen is usually immunized with a physiological condition
  • an adjuvant for example incomplete or complete Freund's adjuvant or Gerbu adjuvant is added.
  • the resulting dilution or emulsion can be, for example, subcutaneously, intramuscularly, intraperitoneally, intravenously or to the mammal can also be administered in other ways.
  • the frequency of administration can be determined in the usual way. For example, subcutaneous administration is customary every two to four weeks for 1 to 10 months, for example 1 to 3 months.
  • the animals are killed.
  • the antibodies are obtained from the blood of the immunized animals by centrifuging the blood and separating the serum. If necessary, the antibodies can be removed from the serum, for example by salting out, by absorption.
  • the formation of specific anti-N-glycolylneuraminic acid antibodies in the serum of the mammals is detected with the aid of the antigen.
  • the immunization was carried out, for example, with a trisaccharide of formula I coupled to KLH, then specifically the Hapten-binding antibodies were detected by testing with trisaccharides coupled to BSA, and cells from the animals with the highest antibody titer and the lowest cross-reactivity were selected for cell fusion to produce hybridoma cells.
  • the monoclonal antibodies according to the invention and the hybridoma cells producing them can be prepared by conventional methods known in the art (G. Koehler and C. Milstein, Nature 256: 495, 1975).
  • antibody-producing cells of the selected immunized animals for example B lymphocytes or spleen cells
  • myeloma cells of a suitable cell line in the presence of known fusion promoters, for example paramyxoviruses, Ca ions, lysolecithin or in particular polyethylene glycol.
  • myeloma cell lines which lack the gene hypoxanthine guanine phosphoribosyl transferase (HGPRT) or the enzyme thymidine kinase (TK) and which therefore contain hypoxanthine, aminophene and thymidine in a selective culture medium (HAT medium), not survive.
  • HGPRT hypoxanthine guanine phosphoribosyl transferase
  • TK thymidine kinase
  • Myeloma cell lines which do not secrete immunoglobulins or parts thereof are particularly preferred.
  • Suitable myeloma cell lines are, for example, the PAI cell lines which are available from J.W. Stocker et al. (Res. Disclos. 217: 155; 1982).
  • the cells are divided and cultivated in selective HAT medium, only hybridoma cell lines surviving because they are from the myeloma cell lines have acquired the ability to grow in vitro and, from the antibody-producing cells of the immunized animals, the missing HGPRT or TK genes and thus the ability to survive in HAT medium.
  • the hybridoma cells are then unsupplemented or supplemented, for example with fetal calf serum, in conventional standard culture media, for example DMEM or RPMI 1640 medium.
  • the cell culture supernatants are examined to determine whether they contain the desired monoclonal antibodies.
  • the specificity of the new antibodies can be demonstrated by a positive reaction with the oligosaccharide antigen according to the invention, or with glycoproteins which comprise N-glycan chains with a terminally glycosidically bound N-glycolylneuraminic acid.
  • antibodies which bind specifically to the hapten are preferably detected by testing with trisaccharides of the formula I which are coupled to BSA. Positive clones which specifically recognize the antigen are then subsequently tested differentially for their cross-reactivity with glycoproteins which only comprise N-glycan chains with terminal N-acetylneuraminic acid, but no N-glycan chains with terminal N-glycolylneuraminic acid. Antibodies that specifically bind to glycoproteins with terminal N-glycolylneuraminic acid are selected.
  • Antibodies with the properties according to the invention are preferred, those of hybridoma cells obtained by fusion of mouse spleen cells with PAI cells, for example the hybridoma cells NGNA-1A3, NGNA-3H5, NGNA-6G5 obtained by fusion of spleen cells of NMRI mice with PAI cells and NGNA-7A4.
  • the hybridoma cells NGNA-1A3, NGNA-3H5, NGNA-6G5 and NGNA-7A4 were sold on September 10, 2002 according to the Budapest contract at the "DSMZ - German Collection of Microorganisms and Cell Cultures GmbH", Mascheroder Weg 1 b, D-38124 Braunschweig, Germany, and received the accession numbers DSM ACC2573, DSM ACC2574, DSM ACC2575 and DSM ACC2576.
  • the invention further relates to the use of the antibodies or derivatives according to the invention formed by the hybridoma cells in an immunoassay for the quantitative or qualitative determination of glycoproteins which comprise N-glycan chains with a terminally glycosidically bound N-glycolylneuraminic acid.
  • Immunoassay is understood here to mean any determination method in which use is made of the antigen-antibody reaction between glycoproteins which comprise N-glycan chains with a terminally glycosidically bound N-glycolylneuraminic acid and the antibodies according to the invention or their derivatives. Such glycoproteins can also be determined in the presence of appropriate homologous endogenous human proteins. The determination of glycoproteins in biological material, for example human or non-human body fluids such as blood and urine, is of particular interest.
  • Glycoproteins that can be determined and detected in this way are, for example, recombinant glycoproteins produced in non-human eukaryotic cells, for example CHO cells, BHK cells or insect cells with baculoviruses as expression systems, for example recombinant human glycoproteins such as recombinant human EPO ,
  • the antibodies or derivatives according to the invention can be used in any of the immunoassays known per se, for example in radioimmunoassays (RIA), enzyme immunoassays (EIA or ELISA), immunofluorescence assays (IFA) and immuno-PCR or -LCR.
  • RIA radioimmunoassays
  • EIA enzyme immunoassays
  • IFA immunofluorescence assays
  • immuno-PCR or -LCR immuno-PCR or -LCR.
  • the assays can be used in any of the known embodiments, for example as homogeneous phase assays, as solid phase assays, as indirect or direct assays, as sandwich assays, as assays with competitive inhibition, in immunoblot methods such as "Western blotting" or as temporally
  • the determination of the glycoproteins can also be carried out by measuring the shift in the elution or migration time of a complex of glycoprotein and antibody compared to its pure elution or migration time in liquid chromatographic and electrophoretic methods.
  • Recombinant human EPO expressed in CHO cells can be advantageously detected, for example, by adding one Examining sample first either directly or indirectly, for example via polyclonal or monoclonal anti-EPO antibodies, which are specific for EPO but cannot differentiate the target molecules, covalently or non-covalently to a suitable carrier, for example plastic surfaces made of polystyrene or polypropylene, nitrocellulose - Membranes or glass beads bind. The mixture is then incubated with monoclonal antibodies according to the invention, for example mouse antibodies. The bound antibodies are then detected with an anti-mouse antibody.
  • a suitable carrier for example plastic surfaces made of polystyrene or polypropylene, nitrocellulose - Membranes or glass beads bind.
  • monoclonal antibodies according to the invention for example mouse antibodies.
  • the bound antibodies are then detected with an anti-mouse antibody.
  • an anti-mouse antibody can be used which is conjugated with alkaline phosphatase or with peroxidase or is provided with a fluorescent marker or a radioactive marker, as a result of which a measurable staining, fluorescence or chemiluminescence reaction takes place or that Radioactivity is detected.
  • the antibodies or the immunoassays of the present invention are therefore particularly suitable for detecting recombinant human glycoproteins in the presence of the corresponding homologous endogenous proteins. They can therefore be used to advantage in medical research and doping analysis.
  • the Neu5Gc- ⁇ - (2- 3 ') - lactosamine-3-aminopropylglycoside of the formula III was prepared in accordance with reaction scheme I, in which Bz is a benzoyl radical, Bn is a benzyl radical and Boc is a tert-butoxycarbonyl radical, starting from the sialyl donor Phenyl [methyl-5-acetamido-4,7,8,9-tetra-0-acetyl-3,5-dideoxy-2-thio-D-glycero- ⁇ , ⁇ -D-galacto-2-nonulopyranoside ionate ( 2), which is available as described by A. Marra and P. Sinay (Carbohydr.
  • the starting material 2 is refluxed with Boc 2 0 and 4-dimethylaminopyridine (DMAP) in dry THF, as in AA Sherman et al. (Carbohydr. Res. 330: 445-458, 2001), to phenyl [methyl-4,7,8,9-tetra-0-acetyl-5- (N-tert-butoxy-carbonylacetamido) -3,5- dideoxy-2-thio-D-glycero-, ß-D-galacto-2-nonulo- pyranoside ionate (3) reacted (i), which is subsequently converted into compound 4 by complete N- and O-deacetylation in MeOH / MeONa (ii) and per-O-acetylation with Ac 2 0 in pyridine (iii).
  • DMAP 4-dimethylaminopyridine
  • the Neu5Gc- ⁇ - (2 ⁇ 3 ') -lactosamine-3-aminopropylglycoside of the formula III obtained as described above was coupled with KLH as a carrier for the production of antigen conjugates.
  • this oligosaccharide antigen was also coupled with BSA as a carrier.
  • the coupling to the carrier was carried out using glutaraldehyde / NaBH 3 CN (GT Hermanson, loc. Cit.).
  • the conjugates were purified by gel filtration (Superdex 75).
  • sialyllactose-BSA conjugate was prepared using commercially available ⁇ 2,3-sialyllactose.
  • mice 2 strains, Balb / c and NMRI were immunized 4 x at intervals of 14 days with the KLH conjugate and adjuvant prepared as above (100 ⁇ g per mouse and injection). Complete Freund's adjuvant was used as adjuvant. The immune response was tested in the ELISA for BSA-NGNA conjugate. 14 days later, two selected NMRI mice with which the best results had been obtained received 3 injections on successive days (KLH conjugate in PBS (10 mM sodium / potassium phosphate, pH 7.2, 0.8% NaCl, 0.02 % KCI); 100 ⁇ g per mouse and injection). These follow-up injections were made with incomplete Freund's adjuvant.
  • PBS 10 mM sodium / potassium phosphate, pH 7.2, 0.8% NaCl, 0.02 % KCI
  • mice were sacrificed and the spleens removed.
  • the spleen cells were isolated and used to produce hybridomas with non-producing myeloma cells (PAI cells, JW Stocker et al., Res. Disclos. 21713, 1982) according to the method of Köhler and Milstein (G. Köhler and C. Milstein, op. Cit.) merged.
  • Hybridomas which recognized the NGNA-BSA conjugate and the recombinant EPO were recloned, stabilized and cryopreserved in a manner known per se.
  • NGNA-1A3 (DSM ACC2573), NGNA-3H5 (DSM ACC2574), NGNA-6G5 (DSM ACC2575) and NGNA-7A4 (DSM ACC2576)
  • monoclonal antibodies were isolated from serum-free cell culture supernatants by means of thiophilic adsorption chromatography (AT-POROS 50-OH, nanoTools Antibodytechnik GmbH and Co KG, Teningen, Germany) and subsequent gel filtration (Superdex 200). The quality of the antibodies was checked by the Lämmli method using SDS-PAGE under reducing conditions and the antibody concentration was determined by measuring the OD 280 . The antibodies could all be assigned to the IgG1 K subclass.
  • the immune response was tested and the reactivity of the antibodies against NGNA was determined by means of ELISA.
  • the ELISA plates were coated with NGNA-BSA conjugate, sialyllactose-BSA conjugate or with various glycoproteins.
  • Dilution series of the mouse sera (in 1% BSA / PBS) were used to test the immune response in the ELISA.
  • Cell culture supernatants of the hybridoma cells for the identification of positive fusion products in the ELISA were used undiluted.
  • Defined antibody concentrates were used to characterize the respective antibodies in the ELISA, whereby dilution series were prepared starting from a starting dilution of 4 ⁇ g / ml.
  • Ready-to-use ELISA plates were incubated with serum dilutions, cell culture supernatants or antibody dilutions (50 ⁇ l per well) for 1 h at room temperature and washed 5 times with PBS. After incubation with the second antibody, goat-anti-mouse-IgG-HRPO (dilution 1: 5000, 1 h, room temperature), the mixture was washed again 5 times with PBS and with 2,2'-azino-bis (3-ethylbenzthiazolinesulfonic acid) (ABTS) developed (OD 415 ).
  • ABTS 2,2'-azino-bis (3-ethylbenzthiazolinesulfonic acid)
  • NGNA-1A3 (DSM ACC2573), NGNA-3H5 (DSM ACC2574), NGNA-6G5 (DSM ACC2575) and NGNA-7A4 (DSM ACC2576) were analyzed by ELISA for their reactivity with NGNA -BSA and silyllactose-BSA conjugates compared. The reactivity was determined by means of dilution series (starting concentration 4 ⁇ g / ml). The results are summarized in Table 2 below. The antibody concentration required to generate a signal> twice the background is given in nanograms per milliliter. Table 2
  • NGNA-1A3 2.0ng / ml 1000ng / ml
  • NGNA-6G5 2.0ng / ml 1000ng / ml
  • NGNA-7A4 2.0ng / ml 1000ng / ml
  • the above monoclonal antibodies were further compared by ELISA as described above with regard to their reactivity to recombinant EPO and IFN-ß protein produced in CHO cells.
  • NGNA-1A3 0.5 ug / ml 2.0 ug / ml
  • NGNA-3H5 0.5 ug / ml 2.0 ug / ml
  • NGNA-6G5 0.5 ug / ml 1,0 ug / ml
  • NGNA-7A4 1.0 ⁇ g / ml 2.0 ⁇ g / ml
  • glycoproteins mucin type II Sigma M 1778
  • glycophorin MM Sigma G7903
  • glycophorin NN Sigma G5017
  • These glycoproteins contain O- and N-linked oligosaccharides with N-acetylneuraminic acid (NANA) in the ⁇ .2.3 and ⁇ 2.6 positions, respectively.
  • NANA N-acetylneuraminic acid

Abstract

L'invention concerne des anticorps monoclonaux se fixant en particulier sur des glycoprotéines, qui comprennent des chaînes N-glycane avec un acide N-glykyl-neuraminique fixé par voie glycosidique en position terminale, et des cellules hybridomes qui produisent de tels anticorps. Lesdits anticorps peuvent s'utiliser dans des immuno-essais pour déterminer la présence par exemple de glycoprotéines humaines recombinées.
EP02785382A 2001-11-09 2002-11-11 Anticorps a anti-n-glycolyl-acide neuraminique et leur utilisation pour determiner la presence de glycoproteines Withdrawn EP1442063A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10155081 2001-11-09
DE10155081 2001-11-09
PCT/EP2002/012579 WO2003040185A2 (fr) 2001-11-09 2002-11-11 Anticorps a anti-n-glycolyl-acide neuraminique et leur utilisation pour determiner la presence de glycoproteines

Publications (1)

Publication Number Publication Date
EP1442063A2 true EP1442063A2 (fr) 2004-08-04

Family

ID=7705189

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02785382A Withdrawn EP1442063A2 (fr) 2001-11-09 2002-11-11 Anticorps a anti-n-glycolyl-acide neuraminique et leur utilisation pour determiner la presence de glycoproteines

Country Status (2)

Country Link
EP (1) EP1442063A2 (fr)
WO (1) WO2003040185A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2302390B1 (fr) * 2003-07-15 2013-06-05 The Regents of The University of California Procédés de détection et d'analyse des anticorps spécifiques de l'acide N-glycolylneuraminique (Neu5Gc) dans des matériaux biologiques
WO2013151649A1 (fr) 2012-04-04 2013-10-10 Sialix Inc Composés d'interaction avec des glycanes
CA2967595A1 (fr) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Composes interagissant avec le glycane et procedes d'utilisation
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA3002097A1 (fr) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Composes interagissant avec le glycane et methodes d'utilisation
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
BR112019018043A2 (pt) 2017-03-03 2020-04-07 Seattle Genetics Inc método de tratamento de câncer, e, conjugado de anticorpo-fármaco

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO03040185A3 *

Also Published As

Publication number Publication date
WO2003040185A2 (fr) 2003-05-15
WO2003040185A3 (fr) 2003-09-25

Similar Documents

Publication Publication Date Title
DE69432926T2 (de) Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
CN101432301B (zh) 具有增强的抗炎性和降低的细胞毒性特性的多肽以及相关方法
Maiorella et al. Effect of culture conditions on IgM antibody structure, pharmacokinetics and activity
DE3922873A1 (de) Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen
Richards et al. The binding of IgE to murine Fc epsilon RII is calcium-dependent but not inhibited by carbohydrate.
AT400577B (de) Verfahren zur herstellung eines monoklonalen antikörpers und verfahren zum nachweisen von malignen zellen
Wyss et al. Composition and Sequence Specific Resonance Assignments of the Heterogeneous N-Linked Glycan in the 13.6 kDa Adhesion Domain of Human Cluster of Differentiation 2 (CD2) as Determined by NMR on the Intact Glycoprotein
Zhang et al. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes.
KR0181948B1 (ko) 인체 IgE에 대한 모노클론 항체
Ito et al. Carbohydrates as antigenic determinants of tumor‐associated antigens recognized by monoclonal anti‐tumor antibodies produced in a syngeneic system
EP0339443B1 (fr) Anticorps monoclonal pour la détermination immunologique sélective du peptide (type III) intact de procollagène et de procollagène (type III) dans des sécrétions
EP1442063A2 (fr) Anticorps a anti-n-glycolyl-acide neuraminique et leur utilisation pour determiner la presence de glycoproteines
EP0955361B1 (fr) Anticorps monoclonaux contre des antigènes associés aux tumeurs, procédés de préparation et utilisation
DE19828466A1 (de) Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind
KR960014441B1 (ko) 알파 2-3 결합을 인지하는 단일클론성 항체
EP1942116B1 (fr) Anticorps monoclonaux destinés à la détermination immunologique sélective de formes de laminine hautement moléculaires intactes dans des liquides corporels
EP0289930B1 (fr) Anticorps monoclonal pour la détermination immunologique sélective de procollagène peptide intact (type III) et procollagène (type III) dans les fluides corporels
JP3150991B2 (ja) ハイブリドーマの製造法
DD269165A5 (de) Verfahren zur Herstellung neuer monoklonaler Antikörper gegen Ifn-Omega und deren Verwendung zur Reinigung sowie zum Nachweis von Ifn-Omega
EP2077280B1 (fr) Anticorps specifiques pour la transferrine déficiente en carbohydrate, leur production et utilisation
DE4329004A1 (de) Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
DE3807594C2 (fr)
Ishikawa et al. Involvement of Cell Surface Carbohydrates in the Sexual Cell Fusion of Dictyostelium discoideum: (Dictyostellium discoideum/sexual cell fusion/monoclonal antibodies/surface carbohydrates)
DE19529026C2 (de) Monoklonale Antikörper gegen humanes Interleukin-10
DE3844628C2 (en) New antibodies reactive with N-glycan structures of cell membrane surf

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040414

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20050203

R17C First examination report despatched (corrected)

Effective date: 20050203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070629